Data from Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma

Autor: Alexey V. Danilov, Peter Hurlin, Justin Cidado, Lisa Drew, Prabhjot Kaur, Craig Y. Okada, Erin W. Gilbert, Joelle Wolf, Cody J. Paiva, Olga Danilova, Vi Lam, Scott Best, Nur Bruss, Taylor Hashiguchi

Deregulation of the MYC transcription factor is a key driver in lymphomagenesis. MYC induces global changes in gene expression that contribute to cell growth, proliferation, and oncogenesis by stimulating the activity of RNA polymerases. A key featur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412890042345346738aeab300ae609e8
https://doi.org/10.1158/1535-7163.c.6539653

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Autor: Ahmad S. Halwani, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, Elizabeth H. Cull, Bela Kis, Jorge M. Chaves, Nancy L. Bartlett, Weiyun Ai, Luis de la Cruz-Merino, Locke J. Bryan, Roch Houot, Kim Linton, Javier Briones, Ian Chau, Gottfried R. von Keudell, Hailing Lu, Adam Yakovich, Michael Chen, ter Meulen JH, Sergey Yurasov, Frank J. Hsu, Christopher R. Flowers

Publikováno v: Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

International audience; Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e37e995b7a7e4fb4d45140e66a7303a
https://doi.org/10.1080/10428194.2021.2010057

Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod

Autor: Guang Fan, Edward Kim, Craig Y Okada, Kevin P. White, Abby Wills, R. Samuel Hopkins

Publikováno v: Dermatology Online Journal. 25

A 55-year-old man with relapsing-remitting multiple sclerosis on fingolimod presented to the dermatology clinic with skin lesions on the left temple and cheek. Histopathology showed a diffuse infiltrate of enlarged, atypical lymphocytes throughout th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f243b0966380cce0158250376a514cf4
https://doi.org/10.5070/d3259045508